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Abstract
Objective: To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods: A twelve-week prospective open-label cohort 
study to compare four subgroups according to first-episode schizophrenia patients’ type of drug usage and sex: female aripiprazole (n = 11), male aripiprazole 
(n = 11), female olanzapine (n = 10), and male olanzapine (n = 11) for body mass index, fasting serum triglyceride, total cholesterol, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, and fasting glucose. Results: Aripiprazole may be associated with weight gain in female patients with low-baseline 
weight. Aripiprazole may have an adverse effect of weight and favorable effects of circulating glucose and lipid on female over male schizophrenia patients. The 
aripiprazole–induced changes in glucose and lipid may be independent of body fat storage, especially for female schizophrenia patients. Olanzapine may have 
adverse effects of weight, glucose and lipid profiles on female over male schizophrenic patients. Discussion: Our findings fill the gap in knowledge and provide 
a sex-specific guidance to psychiatrist better tailoring treatment to individual sex-differential characteristics and a key clue to understand the sex-differential 
mechanism of antipsychotics-induced metabolic dysfunction.
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Introduction
The US National Institutes of Health (NIH) has been urging 
identifying sex-specific risks of adverse events in all NIH-funded 
schizophrenia-related researches1. Some individual prevalences 
of metabolic syndrome (MS) components differed statistically 
between male and female schizophrenia patients. Lots of researches 
in schizophrenia patients treated with antipsychotics had reported 
females with higher prevalence of abnormally low high-density 
lipoprotein cholesterol (HDL) than that of males2-7, and the latter 
with higher prevalence of high triglyceride level over the former2,6-8. 
Rezaei et al. had claimed not only low HDL but also high triglyceride 
level of female chronic schizophrenia patients was more prevalent 
than that of male counterparts9. A recent study from China had 
found higher low-density lipoprotein cholesterol (LDL) (but not 
HDL and triglyceride) plasma levels of female than male chronic 
schizophrenia patients10. Another recent study without reporting 
specific antipsychotic drug and time span of antipsychotic treatment 
had found higher levels of serum triglyceride and LDL as well as 
lower level of HDL in male first-episode schizophrenia patients from 
China than female counterparts11. Most researchers did not find sex 
difference in prevalence of fasting glucose, except for two studies6,9 
reporting higher prevalence of female schizophrenia patients with 
elevated glucose level meeting specific blood glucose criterion of MS 
than that of male counterparts. Despites highly prevalent metabolic 
adverse effects among schizophrenic patients taking antipsychotics, 
the sex-specific data on antipsychotics–induced dyslipidemia 
and impaired glucose metabolism in schizophrenia patients are 
preliminary at best, and show conflicting results. It is therefore 
imperative to indentify sex-differential effects of second-generation 
antipsychotic drugs (SGAs) on glucose and lipid metabolism, 
which is instructive to add some sex-specific therapeutic strategies 
into future clinical psychiatry practice. Among commonly used 
SGAs, undoubtedly, olanzapine is one of the most potential drugs 
inducing weight gain, glucose metabolism abnormalities and/or 
hyperlipidemia, whereas aripiprazole with minimal or no effect on 
glucose and lipid metabolism and the lowest weight-gain liability. 
Therefore, we focus on a sex-differential effect of either olanzapine 
or aripiprazole on body weight and glucose and lipid profiles in 
a population of antipsychotic-naïve first-episode schizophrenia 
patients with monotherapy after hospitalization, and raise the 
following questions: During the first trimester of antipsychotic 
treatment, (1) what were the respective changes in metabolic 
parameters between the sexes and between two drugs from baseline 
to endpoint? (2) what was the interaction between weight gain and 
the changes in glucose and lipid level?
Methods and materials
The study was approved by Jiangxi Mental Health Centre Ethics 
Committee, China, in accordance with the Declaration of Helsinki12. 
A written informed consent was obtained from all study participants 
after the nature of the procedures had been fully explained.
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Participants
Participant enrollment began in February 2015 and ended in October 
2015. A total of forty-three participants (twenty-two men and twenty-
one women) aged 18-48 years were the inpatients from the psychiatric 
units in Jiangxi Mental Health Centre, China. These people were 
experiencing their first psychotic episode of schizophrenia diagnosed 
in accordance with criteria established in DSM-V13 and had not 
previously received any antipsychotic drug treatment.
The exclusion criteria included: any psychiatric disorder other than 
schizophrenia (according to DSM-V); history of any substance–related 
and addictive disorders met DSM-V criteria; a significant risk of 
committing suicide based on history or mental status exam; pregnant 
or lactating patients; specific systemic diseases; or other medical 
conditions such as diabetes mellitus, dyslipidemia, cardiovascular 
diseases, and hypertension; clinically significant abnormal laboratory 
test results, vital sign, or electrocardiogram findings.
Study design
Aripiprazole (Zhejiang Otsuka Pharmaceutical Co. Ltd., China, mean 
20.0 mg/day) or olanzapine (Lilly del Caribe Inc., USA, mean 15.4 
mg/day) monotherapy was not randomized but provided according 
to normal local clinical practice. Participants were divided into 
four groups according to their type of drug usage and sex: female 
aripiprazole (FA), male aripiprazole (MA), female olanzapine (FO), 
and male olanzapine (MO). The primary concerns in present study 
were the comparison on mean changes in metabolic parameters from 
the baseline (i.e., prior to starting either aripiprazole or olanzapine 
treatment) to the fourth, eighth, and twelfth weekend after starting 
the treatment in the four cohorts, including the body mass index 
(BMI), triglyceride (TG), total cholesterol (TC), high density 
lipoprotein cholesterol (HDL), low density lipoprotein cholesterol 
(LDL), and fasting glucose (FG).
All forty-three participants remained hospitalized for the entirety 
of their participation to observe uniform clinical and environmental 
characteristics of the cohorts. They received dietetically balanced 
hospital meals (daily energy intake: men 10.5 MJ (2,500 kcal), women 
9.2 MJ (2,200 kcal)), had occasionally access to meals brought by 
relatives other than being required to attend group, and had the 
opportunity for two hours’ physical exercise each day. No patient 
was concurrently treated with any other drug known to affect serum 
glucose or lipid concentrations or appetite throughout the whole 
study period, also at least one continuous 6-month period before 
enrollment. Only trihexyphenidyl for extrapyramidal symptoms or 
lorazepam for insomnia or agitation was allowed as needed.
Assessments
Height and weight were measured, and BMI was calculated for all 
patients. All patients were rated using the Positive and Negative 
Syndrome Scale14 for their clinical psychotic symptoms by the senior 
psychiatrist trained in its use, with an acceptable minimum score of 
sixty on admission.
Laboratory analyses
Whole venous blood samples were drawn at the early morning of 
the study days after overnight fasting. The fasting serum glucose and 
lipids were analyzed by enzymatic procedure for TC, TG and FG, 
by direct measurement for both HDL and LDL applying the AU680 
Chemistry Analyzer (Beckman Coulter, Inc. USA) in the standard 
clinical biochemistry laboratory.
Statistical analyses
Descriptive statistics were computed for the basic demographic 
and clinical variables. A post hoc longitudinal repeated-measures 
analyses were performed for the mean change from baseline to 
each specified postbaseline visit in the dependent variable (i.e., 
BMI, glucose and lipid) measures between-drug and within-drug, 
as well as between-sex and within-sex with Generalized Additive 
Mixed Model (GAMM), an ideal method analyzing non-normal 
longitudinal data given the fact that the residuals, but not the 
dependent variable, are required to meet the Gaussian distribution 
in this model. In GAMM, the main effect of treatment time, the 
interaction terms of either treatment time × antipsychotic drug 
or treatment time × sex on the evolution of continuous metabolic 
parameters were evaluated. Because the residual analysis of the raw 
datum for BMI failed to met the Gaussian distribution, we took 
the normalized data into the GAMM. The statistical powers of the 
different sample size drawing different inference were presented in 
Stable 1 to Stable 2 from online supplementary content (available 
upon request to the authors).
Al l  ana lyses  were  per formed using Empower  (R) 
(www.empowerstats.com, X and Y solutions, inc. Boston MA) and R 
(http://www.R-project.org) at P ≤ 0.05 levels (two-sided).
Given the crucial effect of the sample size on a test of significance 
in any medical study, we have believed that any inference could come 
not only from data with statistically signiﬁcant difference, but also 
from data with regular, resultantly discernible and traceable pattern 
of change in effect size, despite no statistical signiﬁcance.
Results 
The progress of participants through the study was shown in Figure 1. 
Treatment groups were similar with respect to baseline demographic 
and clinical variables (Table 1).
Body mass index (BMI)
The FA group showed the magnitude significantly increasing in 
the NBMI at every postbaseline visit than baseline in patients with 
aripiprazole. The significant between–sex difference in baseline 
NBMI meant more body weight of MA than FA before aripiprazole 
treatment (Table 2). However, the increase in NBMI of FA overtook 
that of MA month by month during the postbaseline visits (Figure 2), 
meaning aripiprazole–induced weight gain of FA more than that of 
MA. Taken together, these data demonstrate that aripiprazole may 
not only be associated with weight gain in female schizophrenia 
patients with low baseline weight, but also have a more adverse effect 
of weight on female patients than male patients.
Table 1. Baseline demographic and clinical characteristics among 43 
first-episode schizophrenia patients assigned to 12 weeks treatment with 
aripiprazole or olanzapine
Aripiprazole  
(n = 22)
Olanzapine  
(n = 21)
p value
Age (years) 24.18 ± 7.04 28.24 ± 10.57 0.144
Sex, n (%)
Male 11 (50.0%) 11 (52.4%)
Female 11 (50.0%) 10 (47.6%)
Duration of disease (months) 20.52 ± 19.66 14.63 ± 21.01 0.35
PANSS scores 99.95 ± 10.04 104.29 ± 25.83 0.47
BMI 22.0 ± 4.75 21.11 ± 2.77 0.46
Triglyceride concentration (mmol/L) 0.80 ± 0.34 0.82 ± 0.32 0.88
Total cholesterol concentration (mmol/L) 4.24 ± 0.79 4.02 ± 0.79 0.35
LDL concentration (mmol/L) 2.22 ± 0.73 1.97 ± 0.51 0.22
HDL concentration (mmol/L) 1.53 ± 0.37 1.51 ± 0.42 0.85
FG concentration (mmol/L) 5.05 ± 0.64 5.13 ± 0.57 0.65
Data are mean (SD) or n (%). PANSS: the Positive and Negative Syndrome Scale. BMI: body 
mass index; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; 
FG: fasting serum glucose.
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Figure 1. Participant Recruitment and Visit Flow Diagram.
Patient Enrollment February 2015 to October 2015 
Visit Period 
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O Withdrew 
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12 Male 
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(MA) 
14 Female 
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(FO) 
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February 2015 to January 2016 
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Patient Refusal; 333 Medical Exclusion 
Table 2. The between-sex and within-sex evolution of the individual metabolic parameter over time in patients with first-episode schizophrenia assigned 
to 12 weeks treatment with aripiprazole
NBMI NTG NLDL NTC NHDL NFG
Baseline, female -1.07 (-1.61–-0.53)  -0.81 (-1.30–-0.31) -0.23 (-0.81–0.34) -0.03 (-0.59–0.53) 0.52 (-0.02–1.05) 0.20 (-0.42–0.83)
(The 4th weekend - Baseline), female 0.35 (0.18–0.52) 0.66 (0.21–1.11) -0.21 (-0.65–0.22) -0.22 (-0.63–0.19) -0.32 (-0.76–0.13) -0.52 (-1.16–0.12)
(The 8th weekend - Baseline), female 0.53 (0.36–0.70) 0.39 (-0.06–0.84) -0.08 (-0.52–0.35) -0.18 (-0.59–0.24) -0.23 (-0.67–0.21) -0.58 (-1.23–0.06)
(The 12th weekend - Baseline), female 0.75 (0.58–0.92) 0.59 (0.14–1.04) -0.06 (-0.50–0.37) -0.27 (-0.69–0.14) -0.13 (-0.57–0.31) -0.41 (-1.05–0.23)
Baseline × (male - female) 1.49 (0.72–2.25) 0.14 (-0.56–0.84) 0.19 (-0.62–1.00) -0.34 (-1.12–0.45) -0.75 (-1.50–0) -0.07 (-0.95–0.82)
The 4th weekend × (male - female) -0.19 (-0.43–0.05) 0.04 (-0.60–0.68) 0.16 (-0.45–0.78) 0.31 (-0.27–0.89) 0.37 (-0.26–0.99) 0.01 (-0.90–0.92)
The 8th weekend × (male - female) -0.27 (-0.51–0.03) 0.56 (-0.07–1.20) 0.06 (-0.55–0.68) 0.38 (-0.20–0.96) 0.27 (-0.35–0.90) 0.03 (-0.88–0.94)
The 12th weekend × (male - female) -0.28 (-0.52–-0.04), 0.62 (-0.01–1.26) 0.15 (-0.47–0.76) 0.47 (-0.11–1.05) 0.08 (-0.55–0.70) 0.30 (-0.61–1.21)
Data are effect size (95% CI). The measurement units of all laboratory values for the fasting serum levels of lipids and glucose use mmol/L. All indicators are shown by their respective normal score. 
BMI: body mass index; TG: triglyceride; LDL: low-density lipoprotein cholesterol; TC: total cholesterol; HDL: high--density lipoprotein cholesterol; FG: fasting serum glucose.
The significant between–sex difference in baseline NBMI 
meant more body weight of MO than that of FO before olanzapine 
treatment. During the postbaseline visits, however, the weight gain 
of FO significantly exceeded that of MO in turn (Table 3, Figure 2). 
It is thereby demonstrated that olanzapine may have a more adverse 
effect of weight on female patients than male patients.
Serum lipids
Triglyceride (TG)
In view of the smallest magnitude increasing in FA’s NTG compared 
to the other three subgroups, despite its difference respectively 
reaching statistic significance at fourth and twelfth weekend than 
baseline, the effect of aripiprazole on NTG was still considered 
favourable in female patients with schizophrenia. The gradually 
increased between–sex differences in NTG from baseline to 
postbaseline visits in patients with aripiprazole showed more NTG 
gain of the males than that of the females over treatment time (Table 2, 
Figure 2). Taken together, these data demonstrate that aripiprazole 
may have a favourable effect of TG on female over male patients 
with schizophrenia.
The FO group showed the magnitude significantly increasing 
in the NTG at every postbaseline visit than baseline in patients 
with olanzapine. With the progress of treatment, the between-sex 
difference in NTG was made by males more than females at baseline 
into females over males during postbaseline visits. Taken together, 
these data reflect a more adverse effect of olanzapine on TG in female 
patients than that of male patients (Table 3, Figure 2).
The increasing difference in MA’s NTG at every postbaseline 
visit than baseline was much more numerical than the counterpart 
of MA’s NBMI in the male patients (Table 4).
Low density lipoprotein cholesterol (LDL)
The differences decreasing mildly in FA’s NLDL at any postbaseline 
visit than baseline resulted in positive between-sex differences in 
NLDL throughout the whole study period in patients with aripiprazole 
(Table 2, Figure 2), meaning aripiprazole may have a favourable effect 
of LDL on female over male patients with schizophrenia.
The FO group showed the significant increases in postbaseline 
NLDL than baseline so that the magnitude increasing in MO’s NLDL 
were less than that of FO group in patients with olanzapine (Table 3, 
Figure 2), reflecting olanzapine may have an adverse effect of LDL 
on female over male patients with schizophrenia.
Total cholesterol (TC)
The numerically decreasing differences in postbaseline FA’s NTC than 
baseline caused gradually increased between-sex differences in NTC 
at any postbaseline visit than baseline in patients with aripiprazole 
(Table 2, Figure 2), demonstrating aripiprazole may have a favourable 
effect of TC on female over male patients with schizophrenia.
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Figure 2. The Evolution of the Metabolic Parameters from Baseline to the 12th Weekend Between-Drug and Between-Sex in Patients with First-Episode 
Schizophrenia. All indicators are shown by their respective normal score. BMI: body mass index; TG: triglyceride; LDL: low-density lipoprotein cholesterol; 
TC: total cholesterol; HDL: high-density lipoprotein cholesterol; FG: fasting serum glucose. The measurement units of all laboratory values for the fasting 
serum levels of lipids and glucose use mmol/L. What we are concerned about are the slopes of several subgroups, that is, the increasing or decreasing 
magnitude. To make the graphics more intuitive, we thereby have moved the curves of the rest of the subgroups parallel, all starting with the baseline 
values of the MA group. * Sex difference in the aripiprazole group, p < 0.05. ♦ Sex difference in the olanzapine group, p < 0.05.
NBMI
Weeks
BM
I n
or
m
al
 s
co
re
s
0 4
*
*1.35
1.30
1.25
1.20
1.15
1.10
1.05
1.00
0.95
0.90
0.85
0.80
0.75
0.70
0.65
0.60
0.55
0.50
0.45
0.40
8 12
NTC
Weeks
TC
 n
or
m
al
 s
co
re
s
4
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
4
8 12
NHDL
Weeks
HD
L 
no
rm
al
 s
co
re
s
0
0.00
-0.05
-0.10
-0.15
-0.20
-0.25
-0.30
-0.35
-0.40
-0.45
-0.50
-0.55
-0.60
8 12
Weeks
LD
L 
no
rm
al
 s
co
re
s
4
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
8 12
NTG
NLDL
NFG
Weeks
TG
 n
or
m
al
 s
co
re
s
4
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
8 12
Weeks
FG
 n
or
m
al
 s
co
re
s
4
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
-0.05
-0.10
-0.15
-0.20
-0.25
-0.30
-0.35
-0.40
-0.45
-0.50
-0.55
-0.60
8
12
Male Aripiprazole Female Olanzapine  Female Aripiprazole Male Olanzapine
The magnitude increasing in MO’s NTC lagged behind that 
of FO during postbaseline visits, resultantly, negative between-sex 
differences in NTC persisted in patients with olanzapine (Table 3, 
Figure 2), signifying olanzapine may have an adverse effect of TC 
on female over male patients with schizophrenia.
High density lipoprotein cholesterol (HDL)
A negative between-sex difference in baseline NHDL and subsequent 
positive between–sex differences in postbaseline NHDL elucidated 
the amplitude decreasing in postbaseline NHDL of females over 
that of males in patients with aripiprazole (Table 2, Figure 2), 
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Table 3. The between-sex and within-sex evolution of the individual metabolic parameter over time in patients with first-episode schizophrenia assigned 
to 12 weeks treatment with olanzapine
NBMI NTG NLDL NTC NHDL NFG
Baseline, female -0.84 (-1.30–-0.37) -0.91 (-1.47–-0.35) -0.60 (-1.20–-0) -0.50 (-1.10–0.10) 0.46 (-0.14–1.06) 0.43 (-0.13–0.99)
(The 4th weekend - Baseline), female 0.41 (0.24–0.59) 0.83 (0.30–1.36) 0.73 (0.28–1.18) 1.05 (0.58–1.51) 0.22 (-0.30–0.74) -0.21 (-0.89–0.46)
(The 8th weekend - Baseline), female 0.62 (0.44–0.79) 1.31 (0.78–1.84) 0.87 (0.42–1.33) 1.07 (0.61–1.54) 0.16 (-0.36–0.68) -0.08 (-0.76–0.60)
(The 12th weekend - Baseline), female 0.89 (0.72–1.07) 1.76 (1.23–2.29) 1.14 (0.68–1.59) 1.27 (0.81–1.74) -0.37 (-0.89–0.15) -0.39 (-1.06–0.29)
Baseline × (male - female) 0.85 (0.21–1.49) 0.46 (-0.32–1.23) 0.28 (-0.55–1.10) 0.09 (-0.74–0.91) -0.79 (-1.62–0.04) -0.16 (-0.93–0.62)
The 4th weekend × (male - female) -0.16 (-0.40–0.08) -0.14 (-0.87–0.60) -0.16 (-0.79–0.46) -0.60 (-1.24–0.04) -0.48 (-1.19–0.24) 0.37 (-0.56–1.31)
The 8th weekend × (male - female) -0.15 (-0.39–0.09) -0.42 (-1.16–0.31) -0.10 (-0.73–0.52) -0.35 (-0.99–0.29) -0.43 (-1.15–0.29) -0.11 (-1.05–0.82)
The 12th weekend × (male - female) -0.26 (-0.50–-0.02) -0.40 (-1.14–0.33) -0.02 (-0.65–0.60) -0.29 (-0.93–0.35) 0.04 (-0.68–0.76) -0.31 (-1.25–0.62)
Data are effect size (95% CI). The measurement units of all laboratory values for the fasting serum levels of lipids and glucose use mmol/L. All indicators are shown by their respective normal score. 
BMI: body mass index; TG: triglyceride; LDL: low-density lipoprotein cholesterol; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; FG: fasting serum glucose.
meaning aripiprazole may have a slightly more adverse effect of HDL 
metabolism on female patients than that of male patients in our data.
Despite the increases in postbaseline FO’s HDL over that of 
postbaseline MO’s HDL at the fourth and the eighth weekend, with 
the prolongation of treatment time, the former showed a lag behind 
the latter at the twelfth weekend in patients with olanzapine (Table 3, 
Figure 2), elucidating olanzapine may have a more adverse effect of 
HDL metabolism on female patients than male patients.
Fasting glucose (FG)
The overall downward trend in postbaseline FA’s NFG than baseline 
caused a gradually increasing between-sex difference in postbaseline 
NFG in patients with aripiprazole (Table 2, Figure 2), meaning 
there may be an aripiprazole-induced favourable effect of glucose 
metabolism on female over male patients.
The amplitude increasing in postbaseline FO’s NFG than baseline 
exceeded that of MO group in patients with olanzapine, except 
for an isolated change that the former lagged behind the latter at 
the fourth weekend (Table 3, Figure 2), reflecting there may be an 
olanzapine-induced adverse effect of glucose metabolism on female 
over male patients.
Discussion 
We have only included those patients being never exposed to any 
antipsychotic medication prior to the present trial, which facilitated 
us to directly assess independent effects of antipsychotics on glucose 
and lipid metabolism and present the precise effect size of incremental 
metabolic advance between the sexes and between two drugs for 
each metabolic parameter.
Sex difference in weight gain
In a study, the aripiprazole-induced change in weight is not 
associated with baseline weight in schizophrenia patients15. In 
another research, however, aripiprazole is associated with weight 
gain in patients with baseline underweight, with minimal weight 
change in patients with baseline normal weight, and with weight 
loss in patients with baseline overweight16. The research by Kasper 
et al.16. supported our finding that aripiprazole may be responsible 
for weight gain in female schizophrenia patients with low baseline 
weight. Moreover, the previous reports involving in aripiprazole16-18 
and olanzapine17,19 in line with our findings that both olanzapine 
and aripiprazole may have an adverse effect of weight on female 
over male patients strengthen the validity of our interpretations. 
It is argued that either patients with low baseline BMI or female 
patients are more biologically vulnerable to metabolic adversities 
of antipsychotics (such as weight gain)17.
Sex difference in lipid metabolism
Either significant or numerical increase of MA over FA in 
postbaseline NTG, NTC and NLDL as well as slight decrease 
of FA over MA in postbaseline NHDL was observed in patients 
with aripiprazole from our data (Table 2, Figure 2). In general, 
aripiprazole may have a more favourable effect of lipid metabolism 
on female patients than male patients. The previous researches2-7 
supported our findings that both olanzapine and aripiprazole may 
have an adverse effect of HDL metabolism on female over male 
schizophrenia patients. In a recent review identifying lipid level 
in male and female antipsychotic-naïve first-episode psychosis 
patients, however, the amplitude increasing in HDL and TG of 
females exceeds the amplitude decreasing in HDL and TG of males 
after 3-month aripriprazole treatment20. Their data from subjects 
with heterogeneous mental illness and from horizontal rather than 
vertical comparisons may be one of the reasons why their finding is 
less consistent with our observations about an aripriprazole-induced 
adverse effect of HDL and favourable effect of TG on females over 
males. In an early study identifying lipid level in male and female 
antipsychotic–naïve first-episode schizophrenia patients from 
China, triglyceride levels of males were higher than that of females 
at 8-week olanzapine treatment21. The different angle collecting 
data, the distinct method analyzing data and the diverse focus 
reporting data by Wu et al.21 may be the reason of this discrepant 
between-sex result about TG metabolism in schizophrenia patients 
with olanzapine. Moreover, Wu et al. did not pay more attention 
to olanzapine-induced changes in FG and TC in their data, in fact, 
which can give our observations a side support.
Sex difference in fasting glucose (FG)
Crawford and DeLisi’s data20 on FG, TC and LDL support our 
inferences of between-sex difference in effects of aripiprazole on 
these indices, although their data on HDL and TG differed from 
our observations. It is found from our data and others’ researches16,17 
that aripiprazole has the greatest effect on weight gain in those 
female patients with low baseline BMI. Baseline weight of females 
was significantly lower than that of males in our data (Table 2). The 
significant effect of aripiprazole on females’ weight in our subjects 
thus reflected in biochemical indicators in vivo, such as HDL and 
TG, which may be another reason why the between-sex results of 
our two indicators differ from theirs20. HDL and TG may be more 
sensitive to the changes in body weight than other lipid markers in 
schizophrenia patients with antipsychotic treatment.
To our knowledge, we are the first to reveal the sex-dependent 
differences about both an aripiprazole-induced favourable and an 
olanzapine-induced adverse effect of glucose and lipid metabolism 
on female over male antipsychotic-naïve patients with first–episode 
schizophrenia.
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Connection between glucose and lipid metabolism and 
weight gain
The FA group monthly showed the steep rise in postbaseline NBMI, 
either mild decrease in postbaseline NLDL, NTC, NHDL, NFG or 
slight increase in postbaseline NTG than baseline in patients with 
aripiprazole (Table 2, Figure 2). Also, it was not difficult to observe 
that the adverse effect of aripiprazole on NBMI outnumbered on 
NTG in all male patients (Table 4).Therefore, the direct effect of 
aripiprazole on glucose and lipid metabolism may be independent 
of a change in body weight, especially for female patients with 
schizophrenia. Our finding is consistent with previously published 
studies that weight gain was not associated with clinically significant 
changes in glucose and lipid in the patients with aripiprazole18,22. The 
observation that aripiprazole causes weight gain but does not affect 
the level of circulating glucose and lipid has substantial clinical and 
research implications, which mechanism will be explored in deep 
in our next paper.
Numerous clinical studies23 confirmed the association among 
olanzapine administration, weight gain and the aggravation of 
glucose and lipid profiles in the patients with schizophrenia. A study 
in individuals with schizophrenia spectrum disorders on long term 
clozapine or olanzapine treatment within the community reported 
females developed worse metabolic profiles than males24. The findings 
from our data not only support these observations, but also further 
reveal sex difference in metabolic adverse effect of olanzapine on 
patients with first-onset schizophrenia. Given that female patients 
have significantly higher plasma concentrations of olanzapine25,26, and 
require less dose of olanzapine treatment than male patients27, our 
data also confirm that the FO group shows the highest level of glucose 
and lipid deterioration in the four subgroups (Figure 2), we thereby 
advocate the preventive use of the adjunctive agent with antiobesity 
and antidiabetic mechanism at initial exposure to olanzapine against 
metabolic adverse effects secondary to olanzapine administration, 
especially for female patients with schizophrenia. Another good 
alternative may be lower doses, longer dosing intervals of olanzapine 
for female than for male patients with schizophrenia. Certainly, it still 
requires further support from large sample, multi-ethnic, randomized 
controlled trials and the longer–term assessment showing the 
trajectory of metabolic changes to consider this treatment strategy 
as a routine adjuvant therapy to olanzapine administration in future 
revision of therapeutic guidelines.
Conclusion
Despite the unknown exact pharmacological mechanisms 
inducing different pathophysiological processes underlying several 
mutually independent adverse effects (such as weight gain, glucose 
metabolism abnormalities and dyslipidemia), establishing the relative 
contributions of antipsychotics to sex can provide psychiatrists with 
the more targeted SAGs recommends so that they can better tailor 
treatment to individual sex-differential physiological characteristics. 
We hope that some individualized treatment strategies to prescribe 
antipsychotic drugs will emerge in the future clinical psychiatry 
practice, especially one distinguishing between sexes. Furthermore, 
further pathophysiology characterization underlying some sex-
differential effects of aripiprazole and olanzapine on metabolic 
profiles also will provide new clues to develop new pharmacological 
options minimizing SGAs-induced metabolic adverse effects. A 
better understanding of mechanistic connections among glucose 
metabolism abnormalities, lipid disturbances and weight gain 
induced by SGAs may ultimately allow identification of risk factors 
and prevention of those metabolic adverse responses with adjunctive 
approaches in schizophrenia patients.
Limits
First, the sample size of the current study may not be optimal but 
should be sufficient to our conclusions that may guide clinical 
practice. Second, it is seen from Stable 2 (available upon request 
to the authors) that there are two underpowered indicators in the 
aripiprazole group and the olanzapine group, respectively. However, 
any underpowered indicator does not reduce the reliability of our 
inference, because sex differences of glucose and lipid identified by 
us are based not only on their statistical significance but also on their 
patterns in numerical change. In fact, the increase in the probability of 
a type II error resulted from underpowered data precisely strengthens 
our inferences of sex difference in glucose and lipid metabolism.
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Table 4. The between-drug and within-drug evolution of the individual metabolic parameter over time in male patients with first-episode schizophrenia 
assigned to 12 weeks treatment with aripiprazole or olanzapine
NBMI NTG
Baseline, aripiprazole 0.41 (-0.05–0.88) -0.66 (-1.24–-0.09)
(The 4th weekend - Baseline), aripiprazole 0.17 (0.01–0.32) 0.70 (0.22–1.18)
(The 8th weekend - Baseline), aripiprazole 0.26 (0.11–0.42) 0.95 (0.47–1.43)
(The 12th weekend - Baseline), aripiprazole 0.47 (0.32–0.63) 1.21 (0.73–1.69)
Baseline × (olanzapine - aripiprazole) -0.40 (-1.06–0.26) 0.21 (-0.60–1.03)
The 4th weekend × (olanzapine - aripiprazole) 0.08 (-0.13–0.30) 0 (-0.68–0.68)
The 8th weekend × (olanzapine - aripiprazole) 0.21 (-0.01–-0.42) -0.07 (-0.74–0.61)
The 12th weekend × (olanzapine - aripiprazole) 0.16 (-0.06–-0.38) 0.14 (-0.54–0.82)
Data are effect size (95% CI). The measurement units of all laboratory values for the fasting serum levels of lipids and glucose use mmol/L. All indicators are shown by their respective normal score. 
BMI: body mass index; TG: triglyceride.
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On Table 4, where is written:
It should be read:
Table 4. The between-drug and within-drug evolution of the individual metabolic parameter over time in male patients with first-episode schizophrenia 
assigned to 12 weeks treatment with aripiprazole or olanzapine
NBMI NTG
Baseline, female 0.41 (-0.05–0.88) -0.66 (-1.24–-0.09)
(The 4th weekend - Baseline), female 0.17 (0.01–0.32) 0.70 (0.22–1.18)
(The 8th weekend - Baseline), female 0.26 (0.11–0.42) 0.95 (0.47–1.43)
(The 12th weekend - Baseline), female 0.47 (0.32–0.63) 1.21 (0.73–1.69)
Baseline × (male - female) -0.40 (-1.06–0.26) 0.21 (-0.60–1.03)
The 4th weekend × (male - female) 0.08 (-0.13–0.30) 0 (-0.68–0.68)
The 8th weekend × (male - female) 0.21 (-0.01–-0.42) -0.07 (-0.74–0.61)
The 12th weekend × (male - female) 0.16 (-0.06–-0.38) 0.14 (-0.54–0.82)
Data are effect size (95% CI). The measurement units of all laboratory values for the fasting serum levels of lipids and glucose use mmol/L. All indicators are shown by their respective normal score. 
BMI: body mass index; TG: triglyceride.
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